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Joint Effect of Genotypic 
and Phenotypic Features 
of Reproductive Factors on 
Endometrial Cancer Risk
Zhanwei Wang1, Harvey Risch2, Lingeng Lu2, Melinda L. Irwin2, Susan Mayne2,†, 
Peter Schwartz3, Thomas Rutherford3, Immaculata De Vivo4,5 & Herbert Yu1
Prolonged estrogen exposure is believed to be the major cause of endometrial cancer. As possible 
markers of estrogen exposure, various menstrual and reproductive features, e.g., ages at menarche 
and menopause, are found to be associated with endometrial cancer risk. In order to assess their 
combined effects on endometrial cancer, we created the total number of menstrual cycles (TNMC) 
that a woman experienced during her life or up to the time of study and two genetic risk scores, 
GRS1 for age at menarche and GRS2 for age at menopause. Comparing 482 endometrial cancer 
patients with 571 population controls, we found TNMC was associated with endometrial cancer risk 
and that the association remained statistically significant after adjustment for obesity and other 
potential confounders. Risk increased by about 2.5% for every additional 10 menstrual-cycles. The 
study also showed that high GRS1 was associated with increased risk. This relationship, however, 
was attenuated after adjustment for obesity. Our study further indicated women with high TNMC 
and GRS1 had twice the risk of endometrial cancer compared to those low in both indices. Our results 
provided additional support to the involvement of estrogen exposure in endometrial cancer risk with 
regard to genetic background and lifestyle features.
Endometrial cancer is the most frequently diagnosed gynecological cancer in the developed countries, 
and the fourth-most common female malignancy after breast, lung and colorectal cancer1. The develop-
ment of endometrial cancer has been linked to excessive exposure of the uterus to estrogens as well as 
to a relative hormone imbalance between estrogens and progesterone. Prolonged estrogen stimulation of 
endometrial cells can cause abnormal proliferation2, resulting in hyperplasia which can further progress 
to neoplastic transformation. Progesterone opposes the effect of estrogens by down-regulating the con-
centrations of estrogen receptors and promoting endometrial cell differentiation3,4.
Reproductive characteristics, such as parity and ages at menarche, menopause, and first live partu-
rition, reflect, to a certain extent, exposure to endogenous estrogens and progesterone5. Epidemiologic 
studies have shown that early age at menarche, late age at menopause, and nulliparity are all associated 
with increased risk of endometrial cancer, whereas early age at first live birth and multiparity are related 
to reduced risk6–12. Collectively, some studies have used composite measures that incorporate several 
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reproductive and menstrual features to investigate the inferred effects of estrogen exposure on health. 
For example, total number of menstrual cycles (TNMC) has been used to study associations of estrogen 
exposure with breast cancer13,14 and Alzheimer Disease15. No studies to-date have used TNMC to assess 
the relationship between estrogen exposure and endometrial cancer risk.
Common genetic variations have been suspected to be involved in endometrial cancer risk, but to 
date only one single nucleotide polymorphism (SNP), rs4430796 at 17q12 close to HNF1 homeoboxB 
(HNFIB), has been identified by genome-wide association study (GWAS)16,17. GWAS have also found 
a number of SNPs to be associated with ages at menarche18–24 and at natural menopause23–26. Genetic 
risk scoring (GRS) has been used to evaluate the effect of multiple SNPs on associated phenotypes. No 
study has examined reproductive GRS in relation to endometrial cancer risk. In the current study, we 
investigated independent and joint associations of a reproductive composite measure (TNMC) and GRS 
on endometrial cancer risk, with adjustment for other risk factors, such as obesity and sex hormone use.
Results
Characteristics of study subjects. Table 1 shows that the distributions of study variables between 
cases and controls. Compared to controls, cases completed fewer years of education (p = 10−4.2), were 
slightly younger (p = 0.053), more obese (p = 10−26.8), had a greater proportion whose BMI changed 
more than 35% (p = 10−8.4), were more likely to have had induced menopause (p = 10−7.4), were younger 
at menarche (p = 0.005), and were less likely to have used oral contraceptives (p = 0.010). Cases also 
experienced more menstrual cycles than controls, 422.9 versus 396.1 TNMC (p = 10−4.3), and had higher 
genetic risk scores for menarche, either non-weighted GRS1 (p = 0.021) or weighted GRS1 (p = 0.011). 
No difference was found in genetic risk score for menopause, either non-weighted GRS2 (p = 0.97) or 
weighted GRS2 (p = 0.92), nor was age at natural menopause significantly different between cases and 
controls (p = 0.68). In addition, cases and controls were not different in having a family history of cancer 
(p = 0.24) or use of estrogen (p = 0.074).
Genetic risk scores for ages at menarche and natural menopause. From several GWAS reports, 
we identified for GRS calculations 26 menarche-associated and 22 menopause-associated SNPs that 
matched our selection criteria. Supplementary Table S1 lists the SNPs. Some of the reported SNPs did 
not exist in our genotyping data, and therefore proxy SNPs were used that had strong linkage disequilib-
rium with the reported SNPs. Using these SNPs, we calculated GRS1 for early menarche risk and GRS2 
for late menopause risk. Correlations between GRS and ages at menarche and menopause are shown in 
Table 2. These scores had significant linear associations, (β = − 0.27, p = 0.007) between GRS1 and age at 
menarche (i.e., higher score and younger age at menarche) and (β = 0.18, p = 0.009) between GRS2 and 
age at menopause (i.e., higher score and older age at menopause). These associations were similar when 
we used weighted GRS1 and GRS2 (Table 2).
Associations of endometrial cancer with TNMC and GSRs. The associations of endometrial can-
cer risk with TNMC and GRS are shown in Table 3 for all study subjects. Higher TNMC (more menstrual 
cycles) or GRS1 (younger age at menarche) was associated with increased endometrial cancer risk. These 
associations were significant in a dose-response manner (continuous variables). Women with higher than 
median values of TNMC or GRS1 had 65% or 33% increased risk, respectively, in comparison to those 
with values lower than median (categorical variables). Controlling other confounders (age, race and edu-
cation) and risk factors (BMI, OC and estrog en use) did not seem to affect associations with TNMC, but 
exogenous sex hormone use and BMI did affect the disease relationship with GRS1. GRS2 did not show 
any associations with endometrial cancer. To exclude the potential influence of induced menopause on 
our observed associations, we analyzed the data limited to women who had natural menopause (Table 4). 
The results showed little change for TNMC, though GRS1 was no longer significantly associated with 
disease risk. To control for the effect of obesity, we performed subgroup analysis on individuals stratified 
by BMI category (less than 25, between 25 and 30, and 30 or higher). Similar and significant associa-
tions were observed only in those who were overweight (see supplementary Tables S2, S3 and S4). These 
results did not change when weighted GRS1 was used in the analyses.
To assess whether TNMC and GRS1 have joint effects on endometrial cancer, we created a combined 
TNMC-GRS1 variable with four levels. Level one included those with low TNMC and low GRS1 (both 
less than their medians); level two was those with high GRS1 and low TNMC; level three with low GRS1 
and high TNMC; and level four with high GRS1 and high TNMC (both higher than their medians). 
Table 5 shows the results of these analyses. A possible joint effect was indicated between the two factors 
although the interaction term in a logistic regression model was not statistically significant. Women with 
high numbers of total menstrual cycles plus high genetic risk scores for early-age menarche had 2-fold 
increased risk of endometrial cancer. This risk association was slightly attenuated after BMI or BMI 
change was adjusted in the analysis, but the relationship was still statistically significant. Using weighted 
GRS1 did not change the results appreciably.
Discussion
Prolonged unopposed estrogen exposure is believed to be a key risk factor contributing to the devel-
opment of endometrial cancer. Previous studies have investigated in endometrial cancer the roles of 
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several major reproductive and menstrual features that are partially or potentially involved in estrogen 
exposure, such as age at menarche, age at first live parturition, parity number, age at last live parturi-
tion, and age at menopause. Individually, all of these factors have been found to be associated with risk 
of endometrial cancer6–12, but collectively these risk factors have not been studied together for their 
combined effect on risk of the disease. In this case-control study, we developed a composite measure 
that incorporated all of the key reproductive and menstrual features: total number of menstrual cycles 
experienced during life (or up to the time of the study). Our data showed that this new variable was 
Categorical Variable Case (n = 482) No. (%) Control (n = 571) No. (%) P value
Race 0.554
Non white 5(1.04) 4(0.70)
White 477(98.96) 567(99.30)
BMI (kg/m2)^
 < 25 96(21.57) 226(47.48) 10−26.8
 25-< 30 110(24.72) 154(32.35)
 ≥ 30 239(53.71) 96(20.17)
BMI change 10−8.4
 ≤ 5% 9(2.32) 18(4.64)
 > 5%-≤ 20% 76(19.59) 134(34.45)
 > 20%-≤ 35% 102(26.29) 119(30.59)
 > 35% 201(51.80) 118(30.33)
Education 10−4.2
 < 12 yrs. 173(35.89) 150(26.27)
 12 yrs.-3 yrs. College 125(25.93) 122(21.37)
 College/university 92(19.09) 143(25.04)
 Graduate school 92(19.09) 156(27.32)
Menopause status 10−7.4
 Premenopause 60(12.71) 104(18.67)
 Natural menopause 344(72.88) 428(76.84)
 Induced menopause 68(14.41) 25(4.49)
Estrogen use 0.074
 Yes 150(31.91) 201(37.29)
 No 320(68.09) 338(62.71)
OC use 0.010
 Ever 277(57.83) 368(65.60)
 Never 202(42.17) 193(34.40)
Family history of cancer 0.24
 Yes 324(67.22) 364(63.75)
 No 158(32.78) 207(36.25)
Numerical Variable Mean ± SD Mean ± SD
Age (year) 60.55 ± 9.18 61.84 ± 11.12 0.053
Age at menarche (year) 12.30 ± 1.54 12.64 ± 1.60 0.005
Age at natural menopause (year)* 50.91 ± 5.09 50.77 ± 4.15 0.68
Total numbers of menstrual cycles 422.9 ± 101.0 396.1 ± 106.4 10−4.3
Total pregnant months 23.13 ± 12.27 24.78 ± 13.28 0.060
GRS1 27.90 ± 3.78 27.36 ± 3.82 0.021
Weighted GRS1 2.09 ± 0.04 2.03 ± 0.37 0.011
GRS2* 21.43 ± 2.75 21.42 ± 2.68 0.97
Weighted GRS2* 6.343 ± 1.04 6.337 ± 1.01 0.92
Table 1.  Distributions of study variables in endometrial cancer patients and controls. *Subjects with 
induced menopause were excluded (344 cases and 428 controls). ^BMI—5 years before interview.
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significantly associated with endometrial cancer risk; higher numbers of menstrual cycles with higher 
risk of the disease. Quantitatively, each menstrual cycle adds 0.25% to higher endometrial cancer risk. 
Women with TNMC higher than the median number had 56% greater risk of endometrial cancer com-
pared to women with TNMC less than the median. Although the association was slightly attenuated 
after adjusting for obesity, another substantial risk factor for endometrial cancer, the effect of TNMC 
remained statistically significant.
As a composite measure, the total number of menstrual cycles combines both reproductive and 
menstrual features. One of the most important hormonal changes during each menstrual cycle is the 
substantial rise and fall of estradiol levels10. Each menstrual cycle not only represents estrogenic stim-
ulation of the uterus, but also reflects changes in balance between estrogens and progesterone. While 
early adolescent and late perimenopausal cycles tend to be anovulatory, earlier age at menarche and 
later age at menopause may still render a longer term of endometrial exposure to endogenous estrogens. 
Further, lesser parity (or nulliparity) increases the number of menstrual cycles, which also translates into 
more estrogenic stimulation. Thus, collectively the composite measure we developed, i.e., total number 
of menstrual cycles, suggests a relationship with cumulative estrogen exposure. Previous epidemiologic 
studies have shown that women with high numbers of menstrual cycles tend to have higher risk of breast 
cancer13,14. Our study shows that this positive association may also be true for endometrial cancer.
In addition to the use of a composite measure to assess the inferred phenotype of endogenous estro-
gen exposure, we also created two genetic measures, using genetic polymorphisms discovered by GWAS. 
Genetic risk scores were developed for their associations with endometrial cancer risk, one for age at 
menarche (GRS1) and one for age at menopause (GRS2). The method we used to construct genetic 
risk scores is well-established and widely employed by researchers in the genetic field27,28. One of the 
genetic risk scores, age at menarche (GRS1), was significantly associated with endometrial cancer risk, 
without adjustment. The association became insignificant after BMI and other factors were adjusted in 
the analysis, suggesting that such a genetic role in the disease risk may be relatively weak compared to 
environmental exposures and lifestyle factors. In our data, we did find that BMI at age of 20 years was 
inversely correlated with age at menarche, suggesting that age at menarche be influenced both by genetic 
and lifestyle factors. The genetic risk score for menopause (GRS2) was not associated with disease risk. 
Genetic risk score (GRS) βa 95% CI Pb
Age at menarche
 GRS1c
 < 27 0 Reference
 27-< 30 − 0.14 − 0.46 0.19 0.33
 ≥ 30 − 0.39 − 0.71 − 0.07 0.044
 Continuous − 0.27 − 0.47 − 0.08 0.007
Weighed GRS1
 < 1.86 0 Reference
 1.86-< 2.19 − 0.08 − 0.31  0.17 0.55
 ≥ 2.19 − 0.27 − 0.51 − 0.04 0.024
 Continuous − 0.40 − 0.66 − 0.14 0.002
Age at natural menopause
 GRS2d
 < 21 0 Reference
 21-< 24 0.87 0.16 1.59 0.016
 ≥ 24 2.16 1.31 3.01 10−6
 Continuous 0.25 0.13 0.37 10−4.4
Weighed GRS2d
 < 5.85 0 Reference
 5.85-< 6.74 0.66 − 0.12 1.44 0.0002
 ≥ 6.74 1.49 0.71 2.27 0.095
 Continuous 0.57 0.26 0.89 0.0004
Table 2.  Linear regression between GRS and age at menarche or age at natural menopause among 
controls. aMean difference in age at menarche or age at natural menopause. bAdjusted for age and race.  
cGRS1 was calculated based on the 26 SNPs in Table 2. dGRS2 was calculated based on the 22 SNPs  
in Table 2.
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Variable Case/Control ORa 95%CI ORb 95%CI ORc 95%CI ORd 95%CI ORe 95%CI
TNMC
 Continuous* 459/538 1.29 1.14 1.46 1.40 1.22 1.60 1.33 1.15 1.53 1.28 1.10 1.50 1.27 1.07 1.50
 ≤ 411.5 173/269 1.00 1.00 1.00 1.00 1.00
 > 411.5 286/269 1.65 1.28 2.13 1.86 1.42 2.43 1.72 1.29 2.28 1.52 1.10 2.09 1.49 1.07 2.08
GRS1
 Continuous 482/571 1.04 1.01 1.07 1.04 1.00 1.07 1.03 1.00 1.07 1.01 0.97 1.05 1.01 0.97 1.05
 ≤ 27 216/266 1.00 1.00 1.00 1.00 1.00
 > 27 296/275 1.33 1.04 1.69 1.30 1.01 1.66 1.29 1.00 1.68 1.13 0.85 1.50 1.06 0.79 1.43
GRS2
 Continuous 414/546 1.00 0.96 1.05 1.00 0.95 1.05 1.01 0.96 1.07 1.01 0.96 1.07 1.00 0.94 1.06
 ≤ 21 212/275 1.00 1.00 1.00 1.00 1.00
 > 21 202/271 0.97 0.75 1.25 0.98 0.75 1.27 1.01 0.77 1.33 1.06 0.79 1.43 0.97 0.71 1.33
Table 3.  Associations of endometrial cancer with total numbers of menstrual cycles and genetic risk 
scores on menarche and menopause among all subjects. *100 menstrual cycles per unit of increment. ano 
adjustment. badjusted for age, race, and education. cadjusted for age, race, education, family cancer of history, 
OC use, and estrogen. dadjusted for age, race, education, family cancer of history, OC use, estrogen use, and 
BMI. eadjusted for age, race, education, family cancer of history, OC use, estrogen use, and BMI change.
Variable Case/Control ORa 95%CI ORb 95%CI ORc 95%CI ORd 95%CI ORe 95%CI
TNMC
 Continuous* 330/415 1.28 1.09 1.51 1.32 1.11 1.57 1.24 1.04 1.49 1.16 0.95 1.43 1.21 1.00 1.46
 ≤ 424 132/208 1.00 1.00 1.00 1.00 1.00
 > 424 198/207 1.51 1.13 2.02 1.60 1.18 2.17 1.44 1.05 1.99 1.25 0.87 1.79 1.40 1.01 1.95
GRS1
 Continuous 344/428 1.02 0.99 1.06 1.01 0.98 1.05 1.02 0.98 1.06 1.00 0.96 1.04 1.01 0.97 1.05
 ≤ 27 158/216 1.00 1.00 1.00 1.00 1.00
 > 27 186/212 1.20 0.90 1.59 1.14 0.85 1.52 1.19 0.88 1.60 1.11 0.79 1.54 1.12 0.82 1.52
GRS2
 Continuous 344/428 1.01 0.95 1.06 1.00 0.95 1.06 1.00 0.95 1.06 1.00 0.94 1.06 0.99 0.94 1.05
 ≤ 22 226/280 1.00 1.00 1.00 1.00 1.00
 > 22 118/148 0.99 0.73 1.33 0.93 0.68 1.26 0.92 0.67 1.25 0.94 0.66 1.33 0.92 0.67 1.27
Table 4.  Associations of endometrial cancer with total numbers of menstrual cycles and genetic 
risk scores on menarche and menopause among women who had natural menopause. *100 menstrual 
cycles per unit of increment. ano adjustment. badjusted for age, race, and education. cadjusted for age, race, 
education, family cancer of history, OC use, and estrogen use. dadjusted for age, race, education, family 
cancer of history, OC use, estrogen use, and BMI. eadjusted for age, race, education, family cancer of history, 
OC use, estrogen use, and BMI change.
TNMC/GRS1 Case/Control ORa 95%CI ORb 95%CI ORc 95%CI ORd 95%CI ORe 95%CI
Low/Low 69/138 1.00 1.00 1.00 1.00 1.00
Low/High 104/131 1.59 1.08 2.34 1.57 1.06 2.33 1.45 0.97 2.19 1.28 0.81 2.03 0.98 0.59 1.61
High/Low 132/139 1.90 1.31 2.76 2.13 1.44 3.15 1.90 1.26 2.85 1.69 1.07 2.66 1.38 0.85 2.23
High/High 130/154 2.37 1.63 3.44 2.66 1.81 3.93 2.34 1.56 3.51 1.80 1.15 2.84 1.57 0.97 2.53
P for interaction  0.35 0.40 0.55 0.56 0.64
Table 5.  Joint effects of total numbers of menstrual cycles and genetic risk score of menarche on 
endometrial cancer risk. ano adjustment. badjusted for age, race, and education. cadjusted for age, race, 
education, family cancer of history, OC use, and estrogen use. dadjusted for age, race, education, family 
cancer of history, OC use, estrogen use, and BMI. eadjusted for age, race, education, family cancer of history, 
OC use, estrogen use, and BMI change.
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Recently, genetic risk scores have been used to measure combined genetic effects on cancer risk27,29,30. 
Early age at menarche and late age at natural menopause are established risk factors for endometrial 
cancer. It is plausible that SNPs related to age at menarche or age at natural menopause may also influ-
ence cancer risk through their influence on menarche and menopause. Our results demonstrated that 
GRS1, but not GRS2, was associated with endometrial cancer risk. These results were similar to those of 
a meta-analysis in which data from six population-based studies were pooled and analyzed. Compared 
to individuals in the lowest quintile, women in the highest quintiles (4th and 5th) of the genetic risk 
score on age at menarche had odds ratios of 1.14 (95% CI, 1.01 to 1.28) and 1.13 (95% CI, 1.00 to 1.27), 
respectively, for breast cancer27. These observations suggest that estrogen exposure at early ages may be 
more hazardous to the target tissue than exposures at later ages, which is consistent with the notion that 
breast tissue is more sensitive to carcinogens such as ionizing radiation when the tissue is young or at 
an early stage of development. Of course, longer exposure may also be a possible explanation for the 
association with early age menarche.
In addition to TNMC, we also calculated total months of menstrual cycles (TMMC) during life or 
to the time of study, and analyzed its association with endometrial cancer risk. Like TNMC, TMMC 
was also significantly associated with endometrial cancer risk (data not shown). Given that TMMC was 
quite similar to TNMC and that average length of menstrual cycle was not associated with the disease, 
we did not present the results of TMMC analysis in this report. Although an estrogen effect is the major 
underlying mechanism explaining the findings of our analysis, estrogen levels and the balance between 
estrogen and progesterone may not be constant in each menstrual cycle, especially when the cycles are 
anovulatory. Secondary amenorrhea, which was not considered in our TNMC calculation, may also 
be a potential factor influencing our assessment of estrogen effect. Furthermore, the reproductive and 
menstrual parameters used for calculation of the composite variables may have other biological effects 
which are not estrogenic or have additional effects which are independent from their contributions to the 
composite variables. Thus, caution should be exercised when one interprets our results.
Obesity is a strong risk factor for endometrial cancer. Obese women have been reported to have 4 
to 6-fold increases in endometrial cancer risk compared to women with normal weight31,32. Obesity 
may explain 40% of endometrial cancer risk in affluent societies5,33. Long-term overweight and substan-
tial weight gain in early adulthood are also related to the risk of endometrial cancer34–37. In our study, 
we have observed similar associations between obesity and risk of endometrial cancer38. Obesity’s link 
to endometrial cancer has been attributable in part to its influence on estrogen39,40. Obesity increases 
estrogen levels in postmenopausal women and reduces progesterone levels in premenopausal women41. 
To rule out or minimize the influence of obesity on the associations that we found, we adjusted for 
BMI in the logistic regression models. Our results remained significant for the composite measure of 
reproductive features, but not for GRS1. These findings suggest that the estrogenic effect from menstrual 
and reproductive factors may be independent of obesity. The risk effect of genetic determinants is weak 
and less independent of obesity. We also evaluated risk associations with the composite reproductive 
measure and genetic score more specifically by restricting our analysis to subgroups of women stratified 
by BMI categories. Interestingly, these analyses indicated that the associations were mainly seen among 
overweight women. Normal weight and obese women did not show any associations between these 
composite variables and endometrial cancer risk. The observations raise questions regarding the possible 
interaction between obesity and other estrogen-related risk factors in endometrial cancer, but before any 
conclusion can be drawn we need to confirm these findings in additional studies with large sample size. 
In the study, we also found a possible synergy between the composite reproductive measure and genetic 
risk score for age at menarche in association with endometrial cancer risk. This synergy was attenuated 
slightly when BMI was included in the analysis, but remained statistically significant. However, statis-
tically significant interaction between TNMC and GRS for age at menarche was not observed in the 
logistic regression model.
Finally, the results of our study should be interpreted with caution because there are a number of 
inherited methodological limitations. First, the study results were established on the basis of single-site 
investigation with a moderate sample size and inherited possibility for selection bias. Second, some of 
the exposure variables in the study were subject to possible recall bias, though the likelihood and impact 
appeared to be small. Third, these observations need to be confirmed by independent studies. Fourth, 
in calculation of TNMC, we did not consider the potential impact of secondary amenorrhea that some 
women might experience occasionally.
In conclusion, our study suggests that high frequency of menstrual cycles, resulting from long repro-
ductive life, fewer pregnancies and other factors, may play a role in the etiology of endometrial cancer. 
Furthermore, this composite measure appears to have synergistic interactions with common genetic 
polymorphisms that determine early age at menarche, and the synergy is independent of obesity, a strong 
risk factor for endometrial cancer. If our findings can be confirmed by other epidemiologic studies, we 
may consider including the composite measure in risk prediction models for endometrial cancer.
Methods
Study Population. A population-based case-control study was conducted in Connecticut between 
December 2004 and March 2009. The study was approved by the Institutional Review Boards at Yale 
University (IRB number: HIC 0305025270), Connecticut State Department of Health and 28 Connecticut 
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hospitals involved. The methods were carried out in accordance with the approved guidelines. Eligibility of 
the study subjects has been described elsewhere38. Patients with primary endometrial cancer newly diag-
nosed between October 2004 and September 2008 were identified through the Rapid Case Ascertainment 
Shared Resource of the Yale Cancer Center (RCA). Control women, frequency matched to cases on age 
group (35–51, 52–59, 60–64, 65–69, 70–74, and 75–79 years), were recruited through pre-letter assisted 
random-digit residential telephone dialing. After signing a written informed consent, each study partic-
ipant provided a blood sample and underwent an in-person interview using a structured questionnaire 
which ascertained information on demographic features, menstrual and reproductive history, use of 
exogenous hormones, oral contraceptives (OC) use, medical history, family history of cancer, physical 
activity, anthropometric measurements, as well as tobacco smoking, alcohol drinking and dietary habits. 
Subjects with a history of prior cancer diagnosis were excluded from the study.
Total Number of Menstrual Cycles. To evaluate the collective effect of reproductive factors, we 
constructed a total number of menstrual cycles variable (TNMC), which estimated the total number of 
menstrual cycles experienced during life or up to the time of our investigation. This composite measure 
was computed from age at menarche, age at menopause, average length of menstrual cycles, total months 
of all pregnancies, and total months of breastfeeding. TNMC was calculated based on the following 
formula: [(age at menopause − age at menarche) × 12 − total months of all pregnancies − number of live 
births × 1.5 − (total months of breastfeeding)/2 − total months of oral contraceptive use] × 30/average 
length of menstrual cycles (days). Menstrual cycles were assumed to resume at 1.5 months post partu-
rition if no breastfeeding was performed15. If breastfeeding occurred after parturition, we assumed that 
menstrual cycles resumed on average at 1.5 months plus half of the duration of breastfeeding for each 
such parturition. Partial or full breastfeeding was not considered in the calculation. For premenopausal 
women, age at endometrial cancer diagnosis (cases) or study interview (controls) was used as a surrogate 
for “age at menopause” in calculation of TNMC.
Genotype and Genetic Risk Scores. Genomic DNA was isolated from peripheral blood using 
a commercial DNA extraction kit. SNP genotyping was performed using the HumanOmniExpress 
BeadChips (Illumina Inc, San Diego, CA). The BeadChips results were run on an Illumina iScan system 
using the Infinium HD Assay Super Automated Protocol. The GenomeStudio Genotyping (GT) Module 
(Illumina Inc, San Diego, CA) was used for data normalization and genotype calling. After filtering out 
SNPs with completion rates < 90%, minor allele frequencies < 1%, and not in Hardy–Weinberg equilib-
rium (P < 0.0001) among the controls, 1053 subjects including 482 cases and 571 controls with genotype 
information on 649,351 SNPs were included in a previous genome-wide association study (GWAS) of 
endometrial cancer17. This information was used for our construction of genetic risk score (GRS). Two 
types of GRS were calculated. One was non-weighted GRS which was the total number of risk alleles 
among all the SNPs selected for GRS calculation. For each selected SNP, we assigned 0, 1, or 2 to indicate 
the number of risk alleles, assuming an equal and additive effect of each risk allele. The other index was 
a weighted GRS that was the sum of the product of risk allele number and beta coefficient obtained from 
published GWAS results of each SNP. Alleles associated with younger age at menarche or older age at 
natural menopause were defined as risk alleles.
Several GWAS have been published reporting SNPs associated with age at menarche and age at nat-
ural menopause. We selected 26 menarche-associated18–22 and 22 menopause-associated SNPs23–26 to 
construct two Genetic Risk Scores (GRS) for our study, one for menarche (GRS1) and one for menopause 
(GRS2). The criteria for SNP selection included: (a) linkage disequilibrium between SNPs in the same 
gene was low (R2 < 0.5); (b) number of failed genotypes for each SNP was fewer than five study subjects; 
and (c) associations between SNPs and menarche or menopause age had the same direction between our 
study and the GWAS. The few study subjects that had missing SNP genotype information were assigned 
mean risks that were calculated separately in 482 cases and 571 controls, rounded to the nearest whole 
unit. For the 26 SNPs that were not genotyped in our data, highly linked proxy SNPs were selected using 
the 1000 Genome Pilot1 for the CEU population, which is primarily of Northern/Western European 
ancestry (https://www.broadinstitute.org/mpg/snap/ldsearch.php).
Obesity Variable. Body mass index (BMI, kg/m2) was calculated based on self-reported weight and 
height 5 years before interview. BMI was classified into three groups: normal weight (< 25 kg/m2), over-
weight (25 < 30 kg/m2), and obese (≥ 30 kg/m2). In addition to the cross-sectional evaluation, we also 
calculated BMI change over time. BMI change was defined as [(BMI 5 years before interview − BMI at 
20 s)/BMI at 20 s] × 100, and the values were grouped into four categories: BMI change less than or equal 
to 5%, BMI change greater than 5% but less than or equal to 20%, BMI change greater than 20% but less 
than or equal to 35%, and BMI change greater than 35%.
Statistical Analysis. Both continuous and categorical variables were used for data analysis of total 
numbers of menstrual cycles and genetic risk scores. For categorical data, TNMC was classified into four 
groups according to the quartile distribution among control subjects. GRS was divided into three groups 
based on tertile distributions in the controls. Attained age, age at menarche, and age at natural menopause 
were considered as continuous variables. Education was grouped into 4 levels, including less than 12 
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years, 12 years to 3 years of college, completion of college or university, and graduate school. Menopausal 
status was categorized as pre-menopause, natural post-menopause and induced post-menopause. Linear 
regression was used to analyze the associations of GRS with age at menarche and age at natural meno-
pause, with adjustment for age and race. Differences of continuous variables between cases and controls 
were evaluated by Student t statistic. Associations of endometrial cancer risk with TNMC and GRS 
were analyzed using the unconditional logistic regression that yielded odds ratios and 95% confidence 
intervals. Both unadjusted and adjusted models were developed in the analysis, and various multivar-
iable models were created to adjust as appropriate for sets of variables that included age, race, years 
of education, BMI, BMI change, estrogen hormone use, family history of cancer and OC use. Trends 
were examined by considering odds ratios for continuous variables. Associations between SNPs and 
endometrial cancer risk were evaluated by log-additive logistic regression using PLINK (version 1.07; 
http://pngu.mgh.harvard.edu/~purcell/plink/). All other statistical tests were performed with Statistical 
Analysis System (SAS) software (version 9.2, SAS Institute Inc., Cary, NC). All P-values were two-sided.
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